| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/10/2004 | US20040110763 Pyrazolopyridine compound and pharmaceutical use thereof |
| 06/10/2004 | US20040110761 Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| 06/10/2004 | US20040110759 Inhibitors of IkB kinase (I Kappa B Kinase); treating various diseases including asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, cancer, infections, and cardiac infarct |
| 06/10/2004 | US20040110757 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis |
| 06/10/2004 | US20040110756 Anthracene-9-yl-[4-(4-nitro-phenyl)-piperazine-1-yl]-methanone for example; antitumor agents for benign and malignant tumors |
| 06/10/2004 | US20040110754 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders |
| 06/10/2004 | US20040110753 Tyrosine derivatives |
| 06/10/2004 | US20040110752 2-amino-5-((hetero)aryl)-thiazole derivatives; treatment of disorders such as cancer, immunologic disorders and allergic disorders, optionally in combination with other drugs such as immunosuppressants |
| 06/10/2004 | US20040110750 Ortho-diihydroxy- coumarin or 1,2--dihydroquinoline derivatives as catechol-O-methyltransferase enzyme inhibitors for Parkinson*s disease treatment |
| 06/10/2004 | US20040110744 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists |
| 06/10/2004 | US20040110743 Aromatic amine or amide derivatives; neurodegenerative, brain, cardiovascular disorders; spinal cord injuries, encephalitis, cerebral palsy; cognition activators |
| 06/10/2004 | US20040110741 Substituted pyrazolyl compounds for the treatment of inflammation |
| 06/10/2004 | US20040110740 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-(benzoyloxy)-alkyl ester, 4,4-dioxide derivative or solvate; can be mixed with beta-lactam antibiotic |
| 06/10/2004 | US20040110739 Administering precursor of protoporphyrin IX; accumulating therapeutic levels of protoporphyrin IX; photoactivation with light; detecting and treating high speed growth exogenous cells, such as Protista, or parasites |
| 06/10/2004 | US20040110738 Administering silver- or metal compound as microbiocidal, anti-biofilm, bactericidal, antiinflammatory, fungicidal, viricidal and/or anticarcinogenic agent; skin disorders, dentistry |
| 06/10/2004 | US20040110737 Complex derivatives of bis(2-acetylpyridinethiosemicarbazonato-N1,N2,S)gallium(III) as anticarcinogenic agents |
| 06/10/2004 | US20040110736 Cyclic derivatives as modulators of chemokine receptor activity |
| 06/10/2004 | US20040110734 Combinations for the treatment of inflammatory disorders |
| 06/10/2004 | US20040110733 Methods and agents for treating cardiovascular diseases |
| 06/10/2004 | US20040110732 Pharmaceutical composition for transdermal or transmucosal administration comprising at least one progestin and/or at least one oestrogen, process for preparing it and uses thereof |
| 06/10/2004 | US20040110729 Reducing oxidative damage or delaying senescence; oral administration; aging resistance; medical diagnosis, drug srceening; free of nitrones |
| 06/10/2004 | US20040110728 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 06/10/2004 | US20040110726 Treating lameness with an osseous and/or articular component which appear in a person or animal not suffering from fractures or arthritis; horses; veterinary medicine; bone disorders, osteoarthritis |
| 06/10/2004 | US20040110725 Pyridazines as interleukin-1beta converting enzyme inhibitors |
| 06/10/2004 | US20040110724 Enzyme inhibitors and methods therefor |
| 06/10/2004 | US20040110723 Modified psma ligands and uses related thereto |
| 06/10/2004 | US20040110721 Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof |
| 06/10/2004 | US20040110719 Therapeutic use of methionine to reduce the toxicity of platinum-containing anti-tumor compounds |
| 06/10/2004 | US20040110718 Anti-HCV nucleoside derivatives |
| 06/10/2004 | US20040110717 Administering as hepatitis C viricide and inhibiting replication |
| 06/10/2004 | US20040110715 Differs from nucleotide sequence of wild-type IFN alpha -17 gene, in that it comprises one or several SNPs (Single Nucleotide Polymorphism[s]); anticarcinogenic and antiproliferative agents; side effect reduction |
| 06/10/2004 | US20040110712 Methods for treating patients and identifying therapeutics |
| 06/10/2004 | US20040110709 Genetic modification of the lung as a portal for gene delivery |
| 06/10/2004 | US20040110706 Nucleic acid with point mutations, deletions, insertions and/or rearrangements ; hyperthermia, myasthenia, ataxia, neuropathic and inflammatory pain; Alzheimer*s, Parkinson's disease; schizophrenia, hyperekplexia, myotonias and arrhythmia |
| 06/10/2004 | US20040110693 Agent for treating diabetes mellitus |
| 06/10/2004 | US20040110692 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 06/10/2004 | US20040110691 Thiol reactive agents as a therapeutic modality |
| 06/10/2004 | US20040110690 Transporter peptide capable of translocating across biological membrane of pancreatic B-cells, hepatocytes, colon cells, muscle cells and/or lung cells; drug delivery; biochemical conjugation |
| 06/10/2004 | US20040110689 Methods for treating hormone associated conditions using a combination of LHRH antagonists and specific estrogen receptor modulators |
| 06/10/2004 | US20040110684 Genetically engineered caveolin-; antiischemic, antitumor, and wound healing agents; cardiovascular and brain disorders |
| 06/10/2004 | US20040110682 Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use |
| 06/10/2004 | US20040110680 Beta-alethine use in cell culture and therapy |
| 06/10/2004 | US20040110674 Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer |
| 06/10/2004 | US20040110668 Nucleic acid sequences differentially expressed in cancer tissue |
| 06/10/2004 | US20040110663 Hedgehog antagonists, methods and uses related thereto |
| 06/10/2004 | US20040110662 Administering cytotoxic agent and heat shock protein 90 inhibitors such as ansamycins for synergistic growth inhibitors of cells. This therapy as cytotoxic agent and as cell growth inhibitors |
| 06/10/2004 | US20040110661 Rapidly disintegrating tablet comprising an acid-labile active ingredient |
| 06/10/2004 | US20040110257 Production of farnesol and geranylgeraniol |
| 06/10/2004 | US20040110250 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 06/10/2004 | US20040110235 for the treatment of diabetes and other diseases using systematic evolution of ligands by exponential enrichment (SELEX) |
| 06/10/2004 | US20040110229 for treatment/prevention of chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, and urinary incontinence |
| 06/10/2004 | US20040110168 Diagnostics and therapeutics for osteoporosis |
| 06/10/2004 | US20040109920 Coated carotenoid cyclodextrin complexes |
| 06/10/2004 | US20040109902 Dermatological formulations |
| 06/10/2004 | US20040109901 Compositions and methods for nutrition supplementation |
| 06/10/2004 | US20040109898 Mixture of glycerin as fluid carrier and capsicum plant extract; sexual disorders |
| 06/10/2004 | US20040109897 Mixture of solid phthalic dialdehyde, anticaking agent and dispersant |
| 06/10/2004 | US20040109896 Herpes viruse infections of the eyes; aqueous suspension of acyclovir, vinyl acetate-vinyl alcohol copolymer and nonionic surfactant |
| 06/10/2004 | US20040109895 Method and composition for delivering zinc to the nasal membrane |
| 06/10/2004 | US20040109891 Antidiabetic agents |
| 06/10/2004 | US20040109890 Tablets quickly disintegrated in oral cavity |
| 06/10/2004 | US20040109886 Reducing drug abuse of narcotics using drug delivery system |
| 06/10/2004 | US20040109883 Pediculicidal and ovacidal treatment compositions and methods for killing head lice and their eggs |
| 06/10/2004 | US20040109882 Use of flavones, flavanones and flavonoids for protecting ascorbic acid and/or ascorbyl compounds from oxidation |
| 06/10/2004 | US20040109880 Cosmetic and/or pharmaceutical preparations |
| 06/10/2004 | US20040109872 Porifera-based therapeutic compositions for treating and preventing skin diseases |
| 06/10/2004 | US20040109867 Prodrugs of CC-1065 analogs |
| 06/10/2004 | US20040109866 Immonotherapy complex containing antigen, antibodies, epitopes; binding to receptors |
| 06/10/2004 | US20040109859 Method for the treatment of multiple sclerosis |
| 06/10/2004 | US20040109847 Treatment and prophylaxis with 4-1BB-binding agents |
| 06/10/2004 | US20040109846 Restoring cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| 06/10/2004 | US20040109843 Pharmaceutical composition containing decoy and use of the same |
| 06/10/2004 | US20040109835 comprising comb copolymers based on acryloyldimethyltaurine |
| 06/10/2004 | US20040109827 Powdery preparations and proecss for producing the same |
| 06/10/2004 | US20040109826 Stabilized albuterol compositions and method of preparation thereof |
| 06/10/2004 | US20040109825 Elevated temperature storage stable fluid compositions of a delayed-type hypersensitivity (DTH) inducer, e.g., 1-Chloro-2,4 Dinitrobenzene (DNCB) |
| 06/10/2004 | US20040108086 Using Ecteinascidin- 743 drug alone or as part of synergistic mixture |
| 06/10/2004 | CA2840698A1 Materials and methods for preventing and treating microbe-mediated epithelial disorders |
| 06/10/2004 | CA2796924A1 Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors |
| 06/10/2004 | CA2721200A1 Methods of screening for compounds that inhibit the biosynthesis of gpi in malaria parasites |
| 06/10/2004 | CA2691447A1 Ca ix-specific inhibitors |
| 06/10/2004 | CA2589836A1 Target for therapy of cognitive impairment |
| 06/10/2004 | CA2509429A1 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
| 06/10/2004 | CA2507887A1 Nucleotide based medicament and method of use for treatment of conditions in humans |
| 06/10/2004 | CA2507685A1 Process for manufacturing sustained release microbeads containing venlafaxine hci |
| 06/10/2004 | CA2507606A1 Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) |
| 06/10/2004 | CA2507597A1 Halothenoyl-cyclopropane-1-carboxylic acid derivatives |
| 06/10/2004 | CA2507509A1 Therapeutic agent for respiratory disease containing 4-hydroxypiperidine derivative as active ingredient |
| 06/10/2004 | CA2507458A1 Substituted amino phenylacetic acids, derivatives thereof, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors |
| 06/10/2004 | CA2507414A1 Propargyl-trifluoromethoxy-amino-benzothiazole derivatives |
| 06/10/2004 | CA2507392A1 Method of treatment of transplant rejection |
| 06/10/2004 | CA2507356A1 High concentration formulations of opioids and opioid derivatives |
| 06/10/2004 | CA2507273A1 Synergistic anti-cancer composition comprising alpha-ketoglutaric acid, an azonmetnhine former, and n-acetyl-seleno-methionine |
| 06/10/2004 | CA2507266A1 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor |
| 06/10/2004 | CA2507263A1 Liposomal formulations |
| 06/10/2004 | CA2507256A1 Thiazolidine compounds in the treatment of anemic conditions |
| 06/10/2004 | CA2507249A1 Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
| 06/10/2004 | CA2507158A1 Treatment of headache with antipsychotics delivered by inhalation |
| 06/10/2004 | CA2507044A1 Purinergic modulation of smell |
| 06/10/2004 | CA2507018A1 Materials and methods for preventing and treating microbe-mediated epithelial disorders |